[2010, amended 2019] 1.8.4 Use the Collaborative Eclampsia Trial regimen for administration of : A loading dose of 4 g should be given intravenously over 5 to 15 minutes, followed by an infusion of 1 g/hour maintained for 24 hours. If the woman has had an eclamptic fit, the infusion should be continued for 24 hours after the last fit. Recurrent fits should be treated with a further dose of 2 4 g given 1.8.5 Do not use diazepam, phenytoin or other anticonvulsants as an alternative to magnesium sulfate in women with eclampsia. [2010, Antihypertensives 1.8.6 Treat women with severe hypertension who are in critical care during pregnancy or after birth immediately with 1 of the following: labetalol (oral or intravenous) oral nifedipine[3] intravenous hydralazine. [2010, amended 2019] 1.8.7 In women with severe hypertension who are in critical care, monitor their response to treatment: to ensure that their blood pressure falls to identify adverse effects for both the woman and the baby to modify treatment according to response. [2010] 1.8.8 Consider using up to 500 ml crystalloid fluid before or at the same time as the first dose of intravenous hydralazine in the antenatal period. Corticosteroids for fetal lung maturation 1.8.9 If early birth is considered likely within 7 days in women with pre- eclampsia, offer a course of antenatal corticosteroids in line with the NICE guideline on preterm labour and birth. [2010, amended 2019] Corticosteroids to manage HELLP syndrome 1.8.10 Do not use dexamethasone or betamethasone for the treatment of HELLP syndrome. [2010] Fluid balance and volume expansion 1.8.11 Do not use volume expansion in women with severe pre-eclampsia unless hydralazine is the antenatal antihypertensive. 